Provectus adds social media channels for investor updates; discontinues email newsletter

PROVECTUS BIOPHARMACEUTICALS, INC.

Will use Substack, Twitter, and LinkedIn for material disclosures.
Discontinuing its emailed newsletter 'Provectus News'.
Investors encouraged to monitor social media in addition to press releases and SEC filings.

item 7.01

PROVECTUS BIOPHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-012457

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.